Progression of RAS-mutant leukemia during RAF inhibitor treatment (Q39873892)

15 September 2017

Progression of RAS-mutant leukemia during RAF inhibitor treatment (English)

1 reference

15 September 2017

1 reference

1 reference

15 September 2017

Jedd D Wolchok

1 reference

15 September 2017

Margaret K Callahan

1 reference

15 September 2017

Raajit Rampal

1 reference

15 September 2017

James J Harding

1 reference

15 September 2017

Virginia M Klimek

1 reference

15 September 2017

Young Rock Chung

1 reference

15 September 2017

Taha Merghoub

1 reference

15 September 2017

David B Solit

1 reference

15 September 2017

Neal Rosen

1 reference

15 September 2017

Ross L Levine

1 reference

15 September 2017

Paul B Chapman

1 reference

15 September 2017

language of work or name

English

0 references

publication date

7 November 2012

1 reference

The New England Journal of Medicine

15 September 2017

1 reference

15 September 2017

367

1 reference

15 September 2017

1 reference

15 September 2017

2316-2321

1 reference

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

15 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3627494

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3627494

Improved survival with MEK inhibition in BRAF-mutated melanoma

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3627494

Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3627494

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3627494

Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3627494

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3627494

Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3627494

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3627494

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3627494

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3627494

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3627494

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3627494

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3627494

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3627494

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3627494

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3627494

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3627494

Mutations of the BRAF gene in human cancer

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3627494

Paradoxical activation of Raf by a novel Raf inhibitor

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3627494

RAF inhibition and induction of cutaneous squamous cell carcinoma.

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3627494

Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3627494

Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3627494

RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia

2 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23134356

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1056/NEJMOA1208958

1 reference

15 September 2017

1 reference

15 September 2017

PubMed publication ID

23134356

1 reference